<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Product Approval on FinanClub</title>
    <link>https://finan.club/tags/product-approval/</link>
    <description>Recent content in Product Approval on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 18 Aug 2023 09:25:50 +0000</lastBuildDate><atom:link href="https://finan.club/tags/product-approval/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>JNJ</title>
      <link>https://finan.club/us/jnj/</link>
      <pubDate>Fri, 18 Aug 2023 09:25:50 +0000</pubDate>
      
      <guid>https://finan.club/us/jnj/</guid>
      <description>score:47
Chances: JNJ&amp;rsquo;s Pharma and MedTech units are expected to drive sales growth in 2023. Johnson &amp;amp; Johnson is set to split off its consumer health unit, potentially unlocking value. JNJ&amp;rsquo;s key drugs and new products like Darzalex could positively impact Pharma sales.</description>
    </item>
    
    <item>
      <title> ELAN</title>
      <link>https://finan.club/us/elan/</link>
      <pubDate>Tue, 08 Aug 2023 06:17:04 +0000</pubDate>
      
      <guid>https://finan.club/us/elan/</guid>
      <description>score:923
Chances: Elanco Animal Health reports strong financial results for Q2 2023 and raises guidance for the full year. Approval of Elanco&amp;rsquo;s Seresto flea and tick collar by the EPA and FDA contributes to stock surge. Elanco releases Environmental, Social and Governance (ESG) Report highlighting enhanced governance and transparency.</description>
    </item>
    
  </channel>
</rss>
